← Back to Search

Oxygen Delivery Device

High Flow Nasal Cannulas for Respiratory Failure (HDWOBPT Trial)

N/A
Waitlist Available
Research Sponsored by Laval University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Spontaneously breathing patients exhibiting a respiratory distress defined by a respiratory rate ≥ 20 breaths/min associated with either hypoxemia (SpO2<90% with O2≥3L/min) or hypercapnia (PaCO2>45 mmHg with a respiratory acidosis (pH<7,38))
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 minutes
Awards & highlights

HDWOBPT Trial Summary

This trial will study the breathing of 16 patients with respiratory failure who will use high flow nasal cannulas at different flow settings.

Who is the study for?
This trial is for adults with respiratory failure who are breathing on their own but have rapid breathing and either low oxygen levels despite receiving oxygen or high carbon dioxide levels with acidosis. It's not for those under 18, pregnant/breastfeeding women, patients in other studies, or those with certain ear/nose/throat, digestive, rheumatologic/neurologic conditions.Check my eligibility
What is being tested?
The study tests how different flow settings of high flow nasal cannulas affect the work of breathing in patients. Sixteen patients will experience four treatment periods using both conventional masks and a device called Airvo 2; each patient tries all settings in a crossover design.See study design
What are the potential side effects?
While specific side effects aren't listed here, high flow nasal cannula treatments can sometimes cause dryness or irritation in the nose or throat, discomfort from the airflow pressure, and rarely may lead to minor bleeding due to mucosal damage.

HDWOBPT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am breathing on my own but have trouble breathing, with either low oxygen levels or high carbon dioxide levels.

HDWOBPT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 15 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Work of breathing
Secondary outcome measures
Blood gases
Comfort of breathing
Dyspnea
+6 more

HDWOBPT Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: High flow nasal cannulas 60L/minExperimental Treatment1 Intervention
Oxygen delivery via high flow nasal cannulas (60L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.
Group II: High flow nasal cannulas 40L/minExperimental Treatment1 Intervention
Oxygen delivery via high flow nasal cannulas (40L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.
Group III: High flow nasal cannulas 20L/minExperimental Treatment1 Intervention
Oxygen delivery via high flow nasal cannulas (20L/min) with fraction of inspired oxygen (FiO2) adjusted to reach a target SpO2 according to the patient's condition.
Group IV: Conventional flow via nasal prongsActive Control1 Intervention
Oxygen delivery via conventional nasal interface with flow adjusted to reach a target SpO2 according to the patient's condition.

Find a Location

Who is running the clinical trial?

Laval UniversityLead Sponsor
416 Previous Clinical Trials
172,260 Total Patients Enrolled
5 Trials studying Respiratory Failure
600 Patients Enrolled for Respiratory Failure
François Lellouche, MD, PhDStudy DirectorFondation IUCPQ
2 Previous Clinical Trials
40 Total Patients Enrolled
1 Trials studying Respiratory Failure
10 Patients Enrolled for Respiratory Failure

Media Library

Airvo 2; Ficher and Paykel HealthCare (Oxygen Delivery Device) Clinical Trial Eligibility Overview. Trial Name: NCT02494154 — N/A
Respiratory Failure Research Study Groups: High flow nasal cannulas 60L/min, High flow nasal cannulas 40L/min, High flow nasal cannulas 20L/min, Conventional flow via nasal prongs
Respiratory Failure Clinical Trial 2023: Airvo 2; Ficher and Paykel HealthCare Highlights & Side Effects. Trial Name: NCT02494154 — N/A
Airvo 2; Ficher and Paykel HealthCare (Oxygen Delivery Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02494154 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still room for participants in this trial?

"The clinicaltrials.gov website indicates that this medical trial has ceased patient recruitment and is not presently searching for candidates. First posted in May 2015, the study was last updated four months later; however, there are 176 other active trials which may suit potential participants' needs."

Answered by AI
~2 spots leftby Mar 2025